مقاله های علمی- دانشگاهی – . VIREAD (tenofovir disoproxil fumarate).

مقاله های علمی- دانشگاهی – . VIREAD (tenofovir disoproxil fumarate). – 5

ارسال شده در 12 آذر 1401 توسط مدیر سایت در بدون موضوع

. “Submission to the Standing Committee on Industry, Science and Technology”. Bill C-393, An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act. Apotex Inc., October 26, 2010.https://www.apotex.com/global/docs/submission_order_en.pdf, last visited: 10/03/2014. ↑

1. . http://www.apotex.com/ca/en/about/press/20070920.asp. , last visited: 10/03/2014. ↑

1. . WTO; WHO; WIPO. “Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade”. Geneva, 2013, P. 178. ↑

1. . Coenraad Visser, “Patent Exceptions and Limitations in the Health Context”. WIPO, SCP/15/3, ANNEX V, 2010, P. 17.http://www.wipo.int/edocs/mdocs/scp/en/scp_15/scp_15_3-annex1.pdf. , last visited: 10/08/2014. ↑

1. . Nelfinavir. ↑

1. . Efavirenz. ↑

1. . United States Trade Representative(USTR). ↑

1. . “Brazil – Measures Affecting Patent Protection”, Request for Consultations by the United States, WTO, WT/DS199/1, G/L/385, IP/D/23, 8 June 2000.https://docs.wto.org/dol2fe/Pages/FE_Search/DDFDocuments/35212/Q/G/L/385.pdf, last visited: 10/08/2014. ↑

1. . “Brazil – Measures Affecting Patent Protection – Notification of Mutually Agreed Solution”, WTO, WT/DS199/4, G/L/454, IP/D/23/Add.1 19 July 2001.https://docs.wto.org/dol2fe/Pages/FE_Search/FE_S_S009DP.aspx?language=E&CatalogueIdList=34253&CurrentCatalogueIdIndex=0&FullTextSearch=, last visited: 10/09/2014. ↑

1. . Roche Pharmaceutical company. ↑

1. . VIREAD (tenofovir disoproxil fumarate).
  
  ↑

1. . Essential Inventions, Inc. ↑

1. . GLEEVEC (Imatinib Mesylate). ↑

1. . http://www.essentialinventions.org/drug/imatinibmesylate/ei12172004.pdf, last visited: 10/10/2014. ↑

1. . COMBIVIR (lamivudine and zidovudine). ↑

1. . James Packard Love, “Recent examples of the use of compulsory licenses on patents”. Knowledge Ecology International, KEI Research Note 2, 2007, P.14.http://www.keionline.org/misc-docs/recent_cls_8mar07.pdf. , last visited: 10/11/2014. ↑

1. . Abbott Laboratories Pharmaceutical company ↑

1. . ESKE GROUP S.A. ↑

1. . Cipla ↑

1. . http://www.ip-watch.org/2010/04/22/ecuador-grants-first-compulsory-licence-for-hivaids-drug/, last visited: 10/08/2014. ↑

1. . http://www.cptech.org/ip/health/cl/Ghana.png>, last visited: 10/12/2014. ↑

1. . Lamivudine. ↑

1. . Nevirapine. ↑

1. . Stavudine. ↑

1. . Pharco Moçambique Lda. ↑

1. . ARV. ↑

1. . http://www.cptech.org/ip/health/c/mozambique/mozcl-en.pdf, last visited: 10/12/2014. ↑

1. . Hazel Tau. ↑

1. . Treatment Action Campaign (TAC).
  
  ↑

1. . Aspen Pharmacare. ↑

1. . http://www.cptech.org/ip/health/sa/settlement12092003.pdf, last visited: 10/12/2014. ↑

1. . http://www.cptech.org/ip/health/c/thailand/thaicl4efavirenz.html, last visited: 10/12/2014. ↑

1. . http://www.cptech.org/ip/health/c/thailand/thaicl-kaletra_en.pdf, last visited: 10/13/2014. ↑

1. . Clopidogrel Bisulfate. ↑

1. . http://www.cptech.org/ip/health/c/thailand/thaicl-clopidogrel_en.pdf, last visited: 10/13/2014. ↑

1. . Pharco Ltd. ↑

1. . http://www.cptech.org/ip/health/c/zambia/zcl.html, last visited: 10/13/2014. ↑

1. . http://www.cptech.org/ip/health/c/zimbabwe/zim05242002.html, last visited: 10/14/2014. ↑

1. . Antiretroviral Drug. ↑

1. . Varichem Pharmaceutical Company. ↑

1. . Olasupo Ayodeji Owoeye, “Compulsory patent licensing and local drug manufacturing capacity in Africa”. Bull World Health Organ, 2014, P. 215. ↑

1. . Fink.C. “Intellectual Property and Public Health: An Overview of the Debate with a Focus on U.S. Policy”. Center for Global Development, Working Paper Number 146, 2008, P. 8. ↑

1. . WTO; WHO; WIPO. “Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade”. Geneva, 2013, P. 177. ↑

1. . ibid, P. 177. ↑

1. . UNDP, HIV/AIDS Group. “HIV and the Law: Risks, Rights and Health”. Global Commission on HIV and the Law, 2012, P.82.http://www.hivlawcommission.org/resources/report/FinalReport-Risks,Rights&Health-EN.pdf, last visited: 10/14/2014. ↑

1. . Coenraad Visser, “Patent Exceptions and Limitations in the Health Context”. WIPO, SCP/15/3, ANNEX V, 2010, P. 24.http://www.wipo.int/edocs/mdocs/scp/en/scp_15/scp_15_3-annex1.pdf. , last visited: 10/08/2014. ↑

1. . Sisule F. Musungu; Cecilia Oh, “The use of flexibilities in TRIPS by developing countries: can they promote access to medicines?”. Commission on intellectual property rights, innovation and public health (CIPIH), 2005, P. 27.http://www.who.int/intellectualproperty/studies/TRIPSFLEXI.pdf. , last visited: 10/17/2014. ↑